Most breast and ovarian cancers are sporadic, however, a germline pathogenic mutation in BRCA1 or BRCA2 genes is carried in approximately 5% of BC and 10–15% of EOC patients (Alsop et al., 2012; De Talhouet et al., 2020; Rebbeck et al., 2015). This evidence concerns the gene BRCA2 and ovarian cancer.